Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
- DOI
- 10.3389/fimmu.2023.1213920
- Published
- 2023-08-09
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2023.1213920,
title = {Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation},
author = {Guo-Qing Tang and Yalan Tang and Ketki Dhamnaskar and Michelle D. Hoarty and Rohit Vyasamneni and Douangsone D. Vadysirisack and Zhong Ma and Nanqun Zhu and Jian-Guo Wang and Charlie Bu and Bestine Cong and Elizabeth Palmer and Petra W. Duda and Camil Sayegh and Alonso Ricardo},
year = {2023},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2023.1213920},
url = {https://doi.org/10.3389/fimmu.2023.1213920}
}RIS
TY - JOUR TI - Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation AU - Guo-Qing Tang AU - Yalan Tang AU - Ketki Dhamnaskar AU - Michelle D. Hoarty AU - Rohit Vyasamneni AU - Douangsone D. Vadysirisack AU - Zhong Ma AU - Nanqun Zhu AU - Jian-Guo Wang AU - Charlie Bu AU - Bestine Cong AU - Elizabeth Palmer AU - Petra W. Duda AU - Camil Sayegh AU - Alonso Ricardo PY - 2023 JO - Frontiers in Immunology DO - 10.3389/fimmu.2023.1213920 UR - https://doi.org/10.3389/fimmu.2023.1213920 ER -
APA
Tang, G., Tang, Y., Dhamnaskar, K., Hoarty, M. D., Vyasamneni, R., Vadysirisack, D. D., Ma, Z., Zhu, N., Wang, J., Bu, C., Cong, B., Palmer, E., Duda, P. W., Sayegh, C., & Ricardo, A. (2023). Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1213920
Source records
- crossref · retrieved 2026-11-10T12:42:15.646Z